Hinge Health, INC
Market Movers (8-K)
NYSE
Hinge Health announced an increase in its revenue and operating margin guidance for Q2 and full year 2026, coinciding with its inaugural Investor Day event.
Better than expected
NYSE
Hinge Health, Inc. successfully concluded its 2026 Annual Meeting, confirming the election of directors and the appointment of its independent auditor.
NYSE
Hinge Health announced record first quarter 2026 financial results with 47% year-over-year revenue growth and raised its full-year revenue outlook.
Better than expected
NYSE
Hinge Health, Inc. announced the immediate appointment of Tyler Sloat to its Board of Directors, where he will chair the Compensation Committee and serve on the Audit Committee.
NYSE
Hinge Health announced record financial results for the fourth quarter and full year 2025, driven by strong commercial momentum and expanding margins.
Better than expected
NYSE
Hinge Health's Board of Directors authorized a $250 million share repurchase program, signaling confidence in its financial strength and commitment to shareholder returns.
Quarterly Earnings (10-Q)
NYSE
Hinge Health, Inc. announced a 47% year-over-year revenue increase for the first quarter of 2026, driven by strong client retention and member growth.
Better than expected
NYSE
Hinge Health, Inc. reports a 53% revenue increase for Q3 2025, reaching $154.2 million, alongside a significant widening of net loss to $560.4 million for the nine months ended September 30, 2025, primarily due to IPO-related stock-based compensation.
Worse than expected
Capital raise
NYSE
Hinge Health, Inc. announced significant revenue growth and positive cash flow in its latest quarterly report, despite a substantial net loss driven by IPO-related stock-based compensation.
Capital raise
Better than expected
Annual Reports (10-K)
NYSE
Hinge Health reports significant revenue growth and member expansion in 2025, alongside a substantial net loss driven by IPO-related stock compensation.
Capital raise
Worse than expected
Insider Trading (Form 4)
NYSE
Gabriel M.I. Mecklenburg, a Director of Hinge Health, Inc., received 944,250 shares of common stock on July 27, 2026.
NYSE
Daniel Antonio Perez, CEO & Co-Founder, a Director and 10% owner of Hinge Health, Inc., reported multiple transactions in common stock on July 27, 2026.
NYSE
Insight Holdings Group, LLC and affiliated entities reported significant transactions involving Hinge Health, Inc. (HNGE) Class A Common Stock, including conversions and sales.
NYSE
Hinge Health Director Tyler Sloat acquired 246 shares of Class A Common Stock through the settlement of vested RSUs on July 5, 2026.
NYSE
Hinge Health, Inc. Chief Financial Officer, James Budge, reported a transaction involving Class A Common Stock on July 1, 2026.
NYSE
Hinge Health's Exec. Chairman & Co-Founder, Gabriel Mecklenburg, reported transactions involving Class A Common Stock, including acquisitions and dispositions under a Rule 10b5-1 trading plan.
Proxy Statements (Def-14A)
NYSE
Hinge Health, Inc. has issued its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 3, 2026.
New Public Companies (S-1)
NYSE
S-1/A: Hinge Health Files for IPO, Aiming to Revolutionize Musculoskeletal Care with AI-Powered Platform
Hinge Health, a technology platform focused on transforming musculoskeletal care, has filed an S-1/A form for its initial public offering, planning to list on the NYSE under the symbol HNGE.
Capital raise
NYSE
Hinge Health, a digital musculoskeletal (MSK) care company, has filed an S-1/A form with the SEC for its initial public offering (IPO), seeking to transform healthcare delivery through technology and AI.
Better than expected
Capital raise
NYSE
Hinge Health, a technology-driven healthcare company focused on musculoskeletal (MSK) care, has filed an S-1/A form indicating its intent to go public, seeking to transform outcomes, experience, and costs in the healthcare system.
Better than expected
Capital raise
NYSE
Hinge Health, a leading technology platform for musculoskeletal (MSK) care, has filed for an IPO to further its mission of transforming outcomes, experience, and costs through technology.
Better than expected
Capital raise
NYSE
S-1: Hinge Health Files for IPO, Aiming to Revolutionize Musculoskeletal Care with AI-Powered Platform
Hinge Health, a leading technology platform for musculoskeletal (MSK) care, has filed for an IPO, seeking to transform the industry with its AI-powered motion tracking and personalized care programs.
Better than expected
Capital raise
Schedule 13G - Passive Investments
NYSE
Atomico Advisors IV, Ltd. and its affiliates have reported beneficial ownership of 2,300,000 shares of Hinge Health, Inc. Class A Common Stock, representing 2.88% of the class.
NYSE
Hansa Invest, a German investment management company, has disclosed beneficial ownership of 1,476,600 ordinary shares in Hinge Health, Inc., representing 2.7% of the class.
NYSE
The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Hinge Health Inc. following an internal realignment.
NYSE
Daniel Antonio Perez, a U.S. citizen, reported beneficial ownership of 15.7% of Hinge Health, Inc.'s Class A Common Stock as of December 31, 2025.
NYSE
Alkeon Capital Management LLC and its founder, Panayotis D. Sparaggis, have disclosed a 2.1% beneficial ownership stake in Hinge Health, Inc. Class A Common Stock.
NYSE
Insight Partners and its affiliated entities have disclosed a significant 19.8% beneficial ownership stake in Hinge Health, Inc.'s Class A Common Stock.